Document text
Principal Investigator: Jesse Gitaka
Organization: MOUNT KENYA UNIVERSITY
Fiscal Year: 2024
Award: $139,778
Funding agency: National Institute of Allergy and Infectious Diseases
SUMMARY
Coronavirus disease of 2019 (COVID-19) and pulmonary tuberculosis (PTB) have been reported as the
leading causes of mortality from an infectious disease perspective in 2020. TB disease is caused by infection
with Mycobacterium tuberculosis (Mtb), and Kenya remains one of the countries with the highest burden of
TB incidence globally. However, the majority of individuals infected with Mtb never develop active TB, and
are classified as latent infections. Viral infections can increase the risk of reactivation of TB disease, however,
little information is known about the impact of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-
CoV-2) on the reactivation of latent Mtb infection. Exposure to SARS-CoV-2 can increase risk of progression
from latent to active TB through several mechanisms. First, SARS-CoV-2 infection can increase expression
of genes that mediate systemic inflammation, which are known to be associated with heightened risk of
progression to TB disease. Second, SARS-CoV-2 infection can drive differentiation and exhaustion of T cells
that target Mtb antigens and confer protection against progression to disease. Importantly, despite the rollout
of COVID-19 vaccines in low- and middle-income countries, the rate of vaccination remains slow, and
emerging SARS-CoV-2 variants in the region are likely to continue to compromise vaccine efficacy in these
regions. Third, co-infection with COVID-19 and active TB is of concern, hyper inflammatory responses may
induce COVID-19 infection which has the potential of accelerating TB disease. Therefore, the co-evolution
of the TB and COVID-19 pandemics will continue to be a pressing public health concern in the region. In this
study, we will recruit a cohort of latently Mtb infected individuals from 3 major health facilities in two counties
in Kenya (Nairobi and Kiambu), with and without history of exposure to SARS-CoV-2 infections. We will study
the impact of SARS-CoV-2 infections on reactivation of latent TB to TB disease and immunity to Mtb antigens
using a combination of biomarkers and immunological approaches. The QuantiFERON-TB-Gold in Tube
interferon-gamma release assay and a validated serological lateral flow assay specific for immunoglobulin-
G (IgG) antibodies will be used for screening latently infected TB and SARS-CoV-2 exposed participants,
respectively. We will use flow cytometry approach for identification of T cell populations impacted by co-
infection. The practical implication of this work will include identification of patho-immunological mechanisms
at play for TB latent disease reactivation in SARS-CoV-2 exposed individual’s potentially unveiling screening
and therapeutic targets. The work will also build a strong foundation in research network, infrastructure, skills
and data for follow up work on COVID-19 and TB studies in Kenya.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Acceleration><Active Follow-up><Anti Mycobacterial Agents><Antibodies><Antigenic Determinants><Antigens><Antimycobacterial Agents><Assay><Binding Determinants><Bioassay><Biological Assay><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Sample><Blood specimen><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 exposure><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 period><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 patient><COVID19 positive patient><COVID19 virus><CV-19><Cell Communication and Signaling><Cell Signaling><Classification><Clinical><CoV-2><CoV2><Communicable Diseases><Coronavirus Infectious Disease 2019><Country><County><Data><Disease><Disease Progression><Disorder><Epidemiology><Epitopes><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Foundations><Frequencies><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gold><Health Facilities><Health care facility><Healthcare Facility><History><IFN><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IgG><Immune Interferon><Immune response><Immunity><Immunochemical Immunologic><Immunoglobulin G><Immunologic><Immunological><Immunological response><Immunologically><Immunologics><Incidence><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammation><Inflammatory Response><Infrastructure><Interferon Gamma><Interferon Type I><Interferon Type II><Interferons><Intracellular Communication and Signaling><Kenya><LMIC><Lung TB><Lung Tuberculosis><M tb><M tuberculosis><M tuberculosis antigen><M tuberculosis infection><M. tb><M. tb infection><M. tuberculosis><M. tuberculosis antigen><M. tuberculosis infection><M.tb antigen><M.tb infection><M.tuberculosis infection><MTB infection><Measures><Mediating><Mtb antigen><Mycobacterium tuberculosis><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis antigens><Mycobacterium tuberculosis infection><Non-Polyadenylated RNA><Nucleocapsid Proteins><PBMC><Participant><Patients><Peptides><Peripheral Blood Mononuclear Cell><Phenotype><Play><Population><Predicting Risk><Public Health><Pulmonary TB><Pulmonary Tuberculosis><RNA><RNA Gene Products><RT-PCR><RTPCR><Recording of previous events><Reporting><Research><Reverse Transcriptase Polymerase Chain Reaction><Ribonucleic Acid><Risk><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 exposure><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 exposure><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serology><Seroprevalences><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 exposure><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Systematics><T cell response><T memory cell><T-Cell Activation><T-Cell Subsets><T-Cells><T-Lymphocyte><T-Lymphocyte Subsets><T4 Cells><T4 Lymphocytes><TB immunity><TB infection><Transcript Expression Analyses><Transcript Expression Analysis><Tube><Tuberculin Test><Tuberculosis><Vaccination><Viral Diseases><Virus Diseases><Whole Blood><Work><Wuhan coronavirus><activate T cells><active followup><analyze gene expression><antimycobacterial><bio-markers><biologic marker><biological signal transduction><biomarker><care facilities><co-infection><cohort><coinfection><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 exposure><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><disseminated TB><disseminated tuberculosis><epidemiologic><epidemiological><exhaustion><exposure to COVID-19><exposure to SARS-CoV-2><exposure to SARS-CoV2><exposure to Severe acute respiratory syndrome coronavirus 2><exposure to coronavirus disease 2019><flow cytophotometry><follow up><follow-up><followed up><followup><forecasting risk><gene expression analysis><gene expression assay><gene signatures><genetic signature><hCoV19><high risk><histories><host response><immune system response><immunity against M. tuberculosis><immunity against Mtb><immunity against Mycobacterium tuberculosis><immunity against TB><immunity against tuberculosis><immunity in tuberculosis><immunity to TB><immunity to tuberculosis><immunogen><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection due to Mycobacterium tuberculosis><interest><lFN-Gamma><latency/reactivation><latent infection><lateral flow assay><lateral flow test><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><low and middle-income countries><memory T lymphocyte><mortality><mtb><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><predict risk><predict risks><predicted risk><predicted risks><predicting risks><predictive risk><predicts risk><progression risk><reactivation from latency><recruit><respiratory><response><reverse transcriptase PCR><risk prediction><risk predictions><screening><screenings><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><skills><systemic inflammation><systemic inflammatory response><therapeutic target><thymus derived lymphocyte><transcriptional profiling><tuberculin skin test><tuberculosis immunity><tuberculosis infection><tuberculous spondyloarthropathy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine efficacy><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><viral infection><virus infection><virus-induced disease>